Licensing status

Publication and contact information

Infectious disease


Mycobacterium tuberculosis cell division protein FtsZ (MtbftsZ)

In vitro studies identified a new class of MtbftsZ inhibitors that could help treat tuberculosis. SAR studies and in vitro testing of trisubstituted benzimidazoles identified several lead compounds that inhibited the growth of M. tuberculosis, including drug-resistant strains, at nanomolar minimum inhibitory concentrations and without toxicity in normal nonhuman primate cells. Ongoing work includes safety and efficacy testing of several lead compounds in animal models of acute mycobacterial infection.

SciBX 7(2); doi:10.1038/scibx.2014.60
Published online Jan. 16, 2014

Patented by The Research Foundation of The State University of New York; licensed to Sanofi

Awasthi, D. et al. J. Med. Chem.;
published online Nov. 23, 2013;
Contact: Iwao Ojima, Stony Brook University, Stony Brook, N.Y.